Search

Although rates of COVID-19 have remained low among US dentists, the authors aimed to determine the risk of there being COVID-19 in patients seeking oral health care.

This is the first reported case of medication-related osteonecrosis of the jaw (MRONJ) resulting from the use of romosozumab, a new anti-resorptive medication that functions through inhibition of sclerostin. It was approved by the FDA in 2019, and mentioned in the 2022 AAOMS Position Paper on MRONJ. Although initial evidence from animal studies and clinical trials showed a low risk of MRONJ from romosozumab, recent publications on adverse event monitoring demonstrate the need for continued observation and research. Little is known regarding the risk of MRONJ from romosozumab, however, oral surgeons will inevitably be first line clinicians to manage patients on this medication. The purpose of this extremely unusual case report is to improve knowledge and heighten awareness about the association between romosozumab and MRONJ.

Short dental implant placement has become a more popular surgical option for the reconstruction of the dentoalveolar region. In this article, we briefly discuss the considerations that the clinician must take into account when considering the use of short dental implants.

Spindle cell squamous carcinoma (SpCC) is an exceedingly rare variant of squamous cell carcinoma with unique clinicopathological characteristics. SpCC is an aggressive and rapidly progressive neoplasm, and increased awareness for dentists, oral surgeons, and head and neck specialists should aid diagnosis and prompt treatment. We present a case of SpCC in the anterior maxilla of an 84-year-old female which displayed rapid growth.